Clinical Trial Unit

Sr.No Title Sponsor PI Name Department Study status
1 A Phase IV, Prospective, Multicentric, Double-blind, Comparative, Clinical Study to Compare the Efficacy and Safety of Intravenous Ulinastatin versus Placebo along with Standard Supportive Care In Subjects With Severe Sepsis.” Bharat serum PI- Dr. Neelima Chafekar

Co-I: Dr. Gauri Diwan

 Medicine 2017-2022 completed
2 A Multicentric, Randomized, Prospective, Open Label, Comparative, Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Fixed dose combination of Trypsin - Chymotrypsin Enzyme and Diclofenac Oral Tablet in comparison with Diclofenac oral Tablet in the management of acute inflammation due to soft tissue injuries. Torrent pharma PI- Dr. Sudhir Bhamre

Co-I- Dr. Satyen Joshi

 Surgery 2018-2022 completed
3 A Randomized, Double-blind, Parallel, Placebo Controlled, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Cream of Cadila Healthcare Limited with Ketoconazole 2% Cream of Teva Pharmaceuticals USA in Subjects with Tinea Pedis. Cadila Healthcare Limited

(CRO - Cliantha Research Ltd)

 PI: Dr. Vijay Zawar

Co-I: Dr. Bhushan Telhure

 Dermatology 2022

completed

Sr.No Title Sponsor PI Name Department Study status
1 A Phase III Study to Evaluate the Safety and Pharmacokinetics of Methylcobalamin Nasal Spray, 500μg (Torrent Pharmaceuticals) and Compare the Efficacy of Methylcobalamin Nasal Spray, 500μg (Torrent Pharmaceuticals) with Naso B12, 500μg (Troikaa Pharmaceuticals). Torrent Pharmaceuticals PI: Dr. Jitendra Kodilkar Medicine 2019-2021 Completed
2 A Phase III, Randomized, Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b In the Treatment of Adult Patients Diagnosed With SARS-CoV-2 (COVID-19). Cadila Healthcare Ltd (CRO - Zydus) PI- Dr. Kaustubh Mahamine

Co-I: Dr. Shriram Narwade

 Medicine 2021- completed
3 Prospective, Open label, Multicenter, Single Arm, Post Marketing study for evaluation of safety and efficacy of Favipiravir in Adult Indian Patients with Mild to Moderate COVID-19 disease. Glenmark Pharmaceuticals PI: Dr. Ravindra Shinde

Co-I-Dr. Sandip Chaudhary

 Respiratory Medicine 2021- completed
4 A phase III, randomized, multicentre, double blind, placebo controlled, study to evaluate efficacy, safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited Cadila Healthcare Limited (CRO - Zydus) PI- Dr. Kaustubh Mahamine

Co-I: Dr. Ashok Vankudre

 Medicine 2021- completed
5 A Prospective, Randomized, Open-label, Comparative, Multi Centric, Phase III Clinical Study to Evaluate the Efficacy and Safety of Triamcinolone Acetonide and Lignocaine Hydrochloride Oromucosal Gel 0.1%/ 2.0% with Dologel-CT (Choline Salicylate 8.7% w/w, Lignocaine Hydrochloride 2% w/w, and Benzalkonium Chloride 0.01% w/w) in Treatment of Recurrent Aphthous Stomatitis Abbott Ltd PI- Dr. Manisha Marathe

Co-I: Dr. Keshav Handge

 Dental 2021- completed